Journal of Neurology

, Volume 266, Issue 2, pp 530–532 | Cite as

Cannabis use in myotonic dystrophy patients in Germany and USA: a pilot survey

  • Federica Montagnese
  • Molly White
  • Anke Klein
  • Kristina Stahl
  • Stephan Wenninger
  • Benedikt SchoserEmail author
Letter to the Editors

Dear Sirs,

Myotonic dystrophies (DMs) represent the most common form of muscular dystrophies in adulthood. Both forms are characterized by a heterogeneous combination of muscular and multi-systemic symptoms, including weakness, myalgia, myotonia, early cataract, cognitive impairment and diabetes [1]. There is no causal therapy for these conditions and even the symptomatic treatment of some of the most disabling muscular symptoms, myalgia and myotonia, with several analgesics and anti-myotonic drugs is often unsatisfactory [2, 3, 4].

Studies on the use of both medical and non-medical cannabis/cannabinoids have shown some efficacy on chronic pain and spasticity [5]. However, the indication “chronic pain” is wide and pathophysiologically not well defined including different forms of pain (e.g. neuropathic pain, cancer-associated pain, headache, fibromyalgia, etc) which respond differently to cannabis use.

The pathophysiology of myalgia in DMs is still unclear and the potential therapeutic...



We like to thank all members of the Myotonic Dystrophies Foundation MDF, San Francisco, USA, and Diagnosegruppe Myotone Dystrophien, Deutsche Gesellschaft für Muskelkranke, Freiburg Germany for all the enthusiasm and ongoing support for our project, and Nexien Biopharma, Inc. for their support of cannabinoid-based, FDA compliant, solutions to help alleviate the symptoms of DM.


There was no funding for this survey.

Compliance with ethical standards

Conflicts of interest

FM, MW, AK, KS, SW have no conflicts of interest. BS is a scientific advisor of Nexien BioPharma, Inc.

Ethical standard

This study followed the tenets of the Declaration of Helsinki. As this survey was a patient organization (MW, AK) driven survey, done anonymously and blinded, no formal IRB approval was submitted.


  1. 1.
    Wenninger S, Montagnese F, Schoser B (2018) Core clinical phenotypes in myotonic dystrophies. Front Neurol 9:303. CrossRefGoogle Scholar
  2. 2.
    Heatwole C, Johnson N, Bode R, Dekdebrun J, Dilek N, Hilbert JE, Luebbe E, Martens W, McDermott MP, Quinn C, Rothrock N, Thornton C, Vickrey BG, Victorson D, Moxley RT (2015) Patient-reported impact of symptoms in myotonic dystrophy type 2 (PRISM-2). Neurology 85(24):2136–2146. CrossRefGoogle Scholar
  3. 3.
    Heatwole C, Bode R, Johnson N, Quinn C, Martens W, McDermott MP, Rothrock N, Thornton C, Vickrey B, Victorson D, Moxley R (2012) Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1). Neurology 79(4):348–357. CrossRefGoogle Scholar
  4. 4.
    Suokas KI, Haanpää M, Kautiainen H, Udd B, Hietaharju AJ (2012) Pain in patients with myotonic dystrophy type 2: a postal survey in Finland. Muscle Nerve 45(1):70–74. CrossRefGoogle Scholar
  5. 5.
    Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W (2018) Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev 3:CD012182. Google Scholar
  6. 6.
    Sexton M, Cuttler C, Finnell JS, Mischley LK (2016) A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy. Cannabis Cannabinoid Res 1(1):131–138. CrossRefGoogle Scholar
  7. 7.
    Bagüés A, Martín MI, Sánchez-Robles EM (2014) Involvement of central and peripheral cannabinoid receptors on antinociceptive effect of tetrahydrocannabinol in muscle pain. Eur J Pharmacol 745:69–75. CrossRefGoogle Scholar
  8. 8.
    Cavuoto P, McAinch AJ, Hatzinikolas G, Janovská A, Game P, Wittert GA (2007) The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem Biophys Res Commun 364(1):105–10CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of NeurologyFriedrich-Baur-Institute, Ludwig-Maximilians-University MunichMunichGermany
  2. 2.Myotonic Dystrophy FoundationSan FranciscoUSA
  3. 3.Diagnosegruppe Myotone Dystrophien, Deutsche Gesellschaft für Muskelkranke e.V.FreiburgGermany

Personalised recommendations